57 results on '"Ogata, T"'
Search Results
2. [Ⅲ.Fusion Genes in Colorectal Cancer -Diagnosis and Treatment].
- Author
-
Ogata T and Masuishi T
- Subjects
- Humans, Colonic Neoplasms, Colorectal Neoplasms diagnosis, Colorectal Neoplasms genetics, Colorectal Neoplasms therapy
- Published
- 2020
3. [Local Resection of Gastric Tube Cancer with a Gastrointestinal Endoscope].
- Author
-
Osakabe H, Ogata T, Hara K, Nakazono M, Nagasawa S, Kumazu Y, Hayashi T, Yamada T, Katsumata K, Tsuchida A, and Yoshikawa T
- Subjects
- Aged, 80 and over, Endoscopes, Gastrointestinal, Esophagectomy, Humans, Male, Adenocarcinoma surgery, Esophageal Neoplasms surgery, Stomach Neoplasms surgery
- Abstract
An 81-year-old man with esophageal cancer had undergone subtotal thoracic esophagectomy and retrosternal reconstruction using a gastric tube. He developed anemia. Gastrointestinal endoscopy was performed, which revealed a tumor in the posterior wall of the lower part of the gastric tube. Biopsy revealed well-differentiated adenocarcinoma. There was no lymph node metastasis and no distal metastasis on CT. We performed partial resection of the stomach tube because of his age and physical condition. We identified the position of the tumor by upper gastrointestinal series CT and gastrointestinal endoscopy. The tumor was located on the posterior wall of the lower part of the gastric tube and the back of the sternum lower border. Marking was performed by gastrointestinal endoscopy before operation. We simulated the operation and decided to perform laparostomy without sternotomy incision. We cut the anterior wall of the gastric tube in front of the tumor using the endoscope. We could then confirm the diagnosis of cancer, and clipped and removed the tumor from the posterior wall. The resected site was sutured with 4-0 absorbable thread. The pathological diagnosis was T1a(M)N0M0, ly0, v0, PM0, DM0, pStage ⅠA.
- Published
- 2018
4. [A Case of Mediastinal Lymph Node Recurrence after Endoscopic Submucosal Dissection of Esophageal Cancer].
- Author
-
Nagasawa S, Ogata T, Hara K, Osakabe H, Shimoda Y, Nakazono M, Kumazu Y, Hayashi T, Yamada T, Okubo Y, Yokose T, Rino Y, Masuda M, Oshima T, and Yoshikawa T
- Subjects
- Aged, Esophagectomy, Humans, Lymph Node Excision, Lymph Nodes, Male, Neoplasm Recurrence, Local, Endoscopic Mucosal Resection, Esophageal Neoplasms pathology, Esophageal Neoplasms surgery, Lymphatic Metastasis
- Abstract
We report a case of mediastinal lymph node recurrence of esophageal cancer after endoscopic submucosal dissection (ESD). We first administered chemotherapy and then performed esophagectomy. A 78-year-old man underwent ESD for early esophageal cancer at a different hospital in January 2015. H e was diagnosed pathologically with scc, pSM1, pHM1, pVM0, ly0, v0. Additional treatment was not administered because of his age. In June 2017, chest enhanced CT showed swollen mediastinal lymph nodes. This was diagnosed as a recurrence of esophageal cancer, and he presented at our hospital. We first performed chemotherapy for that lesion, because the swollen lymph node was large and may have invaded the surrounding organs. We then performed esophagectomy.
- Published
- 2018
5. [A Case of Liver Metastasis 14 Years after Total Gastrectomy for Advanced Gastric Cancer].
- Author
-
Hara K, Yamada T, Osakabe H, Shimoda Y, Nakazono M, Nagasawa S, Kumazu Y, Hayashi T, Yoshioka E, Yokose T, Rino Y, Masuda M, Ogata T, Oshima T, and Yoshikawa T
- Subjects
- Aged, 80 and over, Anastomosis, Roux-en-Y, Gastrectomy, Humans, Male, Neoplasm Recurrence, Local, Time Factors, Liver Neoplasms secondary, Stomach Neoplasms pathology, Stomach Neoplasms surgery
- Abstract
We report a rare case of liver recurrence of gastric cancer 14 years and 3 months after curative gastrectomy. An 81-yearold man underwent total gastrectomy, D2 lymphadenectomy, Roux-en-Y reconstruction, and cholecystectomy for advanced gastric cancer in November 2002. H e was diagnosed pathologically with M, Type 5, 53×42 mm, tub2>tub1, pT4a, ly2, v2, pN1, pPM0, pDM0, M0, pStage ⅢA(JGCA 15th). Postoperative adjuvant therapy was not administered. He was followed up for 5 years after surgery without adjuvant therapy, and he did not exhibit recurrence. In February 2017, he experienced difficulties in swallowing and visited our hospital. Abdominal contrast-enhanced CT showed an 8×5 cm liver tumor in the lateral segment. Part of the tumor protruded to outside of the liver, and the tumor invaded and pushed the jejunum in the Roux limb. We performed liver biopsy and diagnosed him with liver metastasis of recurrent gastric cancer. Late relapse after gastrectomy, especially after 10 years or more, is very rare.
- Published
- 2018
6. [A Case of Unresectable Advanced Gastric Cancer Treated by Seven Courses of Chemotherapy with Docetaxel, Cisplatin, and S-1Followed by Conversion Surgery Achieved Five Year Relapse Free Survival].
- Author
-
Nakajima T, Cho H, Okubo Y, Kano K, Maezawa Y, Ikeda K, Yamada T, Ogata T, and Yoshikawa T
- Subjects
- Cisplatin administration & dosage, Docetaxel, Drug Combinations, Gastrectomy, Humans, Male, Middle Aged, Neoadjuvant Therapy, Oxonic Acid administration & dosage, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Taxoids administration & dosage, Tegafur administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms drug therapy
- Abstract
The patient is a 51-year-old man.Upper gastrointestinal endoscopy revealed gigantic type 3 gastric cancer.Enhanced abdominal CT demonstrated a gigantic mass of 15×7 cm in the stomach, and a large number of peritoneal dissemination with moderate amount of ascites.The patient was diagnosed with cT4aN3bM1(peritoneal dissemination), Stage IV gastric cancer(JPN ver8)and was treated by chemotherapy with docetaxel(40mg/m / 2 day 1)plus cisplatin(60mg/m2 day 1)plus S-1(80mg/m2 day 1-14).After 7 courses of chemotherapy, peritoneal dissemination was disappeared.The patient received total gastrectomy and D2 lymphadenectomy as a conversion surgery.The pathological findings revealed a T0N0M0, stage 0; the tumor was determined to be Grade 3 owing to the chemotherapeutic effect.Without postoperative adjuvant therapy, the patient is alive without recurrence at the 5 years follow-up after operation.
- Published
- 2018
7. [A Long-Term Survivor Who Are Responding to Sunitinib Treatment for Recurrent Imatinib-Resistant Gastrointestinal Stromal Tumor(GIST)of the Stomach].
- Author
-
Kano K, Cho H, Maezawa Y, Aoyama T, Hayashi T, Yamada T, Sato T, Oshima T, Yukawa N, Rino Y, Masuda M, Ogata T, and Yoshikawa T
- Subjects
- Gastrointestinal Stromal Tumors surgery, Humans, Imatinib Mesylate therapeutic use, Male, Middle Aged, Recurrence, Stomach Neoplasms surgery, Sunitinib, Time Factors, Antineoplastic Agents therapeutic use, Drug Resistance, Neoplasm, Gastrointestinal Stromal Tumors drug therapy, Indoles therapeutic use, Pyrroles therapeutic use, Stomach Neoplasms drug therapy
- Abstract
A 63-year-old man underwent a laparoscopic partial gastrectomy for GIST on September, 2001. Three years and 2 months after the gastrectomy, an abdominal CT showed multiple recurrences in S5 and S6 in the liver and peritoneum. After 4 months from the start of imatinib treatment(400mg/day), peritoneal tumors disappeared and the patient maintained stable disease by imatinib treatment for 8 years. However, on December, 2012, an abdominal CT scan revealed the regrowth of the tumor in S6 in the liver, and PET-CT showed focal progression of only the S6 lesion. Although the lesion was resectable, the patient did not request surgical intervention. So, we initiated sunitinib treatment(50mg/day), and the residual liver metastasis has been well controlled with favorable response of sunitinib for 4 years without severe side effects.
- Published
- 2017
8. [A Case of Roux-en-Y Loop Reconstruction Using a Modified Aboral Pouch Technique for Y-Limb Obstruction Following Distal Gastrectomy].
- Author
-
Kano K, Cho H, Maezawa Y, Aoyama T, Hayashi T, Yamada T, Sato T, Oshima T, Yukawa N, Rino Y, Masuda M, Ogata T, and Yoshikawa T
- Subjects
- Afferent Loop Syndrome etiology, Humans, Male, Middle Aged, Stomach Neoplasms surgery, Treatment Outcome, Afferent Loop Syndrome surgery, Anastomosis, Roux-en-Y methods, Gastrectomy adverse effects
- Abstract
A 53-year-old man underwentdistal gastrectomy with Roux-en-Y(R-Y)reconstruction for gastric cancer. An R-Y anastomosis was performed usinga 21mm circular stapler. Five years postoperatively, he visited our hospital with anorexia. An abdominal computed tomography scan showed dilatation of the afferent loop. He was diagnosed with afferent loop syndrome due to R-Y anastomotic stenosis that resulted in poor oral intake and malnutrition. A U-shaped bend created by an adhesion caused a bowel obstruction of the Y-anastomotic site for which the patient underwent R-Y loop reconstruction with an aboral pouch usinga 60mm linear stapler. He has been well without postoperative complaints. Here, we report a case of R-Y loop reconstruction with an aboral pouch for afferent loop obstruction complicated by stenosis of the Y-anastomotic site after distal gastrectomy.
- Published
- 2017
9. [A Case of Laparoscopic Repair of Internal Hernia after Laparoscope-Assisted Distal Gastrectomy with Antecolic Roux-en-Y Reconstruction].
- Author
-
Maezawa Y, Cho H, Kano K, Nakajima T, Ikeda K, Yamada T, Sato T, Ohshima T, Rino Y, Masuda M, Ogata T, and Yoshikawa T
- Subjects
- Aged, Female, Herniorrhaphy, Humans, Laparoscopy, Anastomosis, Roux-en-Y adverse effects, Gastrectomy adverse effects, Hernia, Intestinal Diseases surgery, Intestine, Small surgery
- Abstract
A 72-year-old woman had undergone laparoscope-assisted distal gastrectomy with D1 plus lymph node dissection and antecolic Roux-en-Y reconstruction for early gastric cancer. She visited our department outpatient clinic with left upper abdominal pain 1 year and 9 months after the surgery. CT revealed a spiral sign of the superior mesenteric arteriovenous branch. An internal hernia was suspected on hospitalization. Although abdominal symptoms were relieved by conservative treatment, the hernia persisted. Laparoscopic surgery was performed and revealed that almost entire small intestine had been affected due to Petersen's defect. Since no ischemic changes were observed, the defect was repaired laparoscopically with suture closure. There has been no recurrence of internal hernia after the laparoscopic surgery. Internal hernia after distal gastrectomy is relatively rare. However, the risk of internal hernia is high due to the gap between the elevated jejunum and transverse colon mesentery in Roux-en-Y reconstruction and can lead to intestinal necrosis. Since an internal hernia can occur in patients who have undergone gastric resection with Roux-en-Y reconstruction, suture closure of Petersen's defect should be performed to prevent this occurrence.
- Published
- 2017
10. [Radical Chemoradiotherapy for Recurrent Esophageal Cancer after Curative Esophagectomy].
- Author
-
Nakajima T, Ogata T, Nomiya T, Nonaka T, Nakayama Y, Kano K, Maezawa Y, Segami K, Ikeda K, Sato T, Cho H, and Yoshikawa T
- Subjects
- Aged, Esophagectomy, Female, Humans, Lymphatic Metastasis, Male, Middle Aged, Recurrence, Treatment Outcome, Chemoradiotherapy, Esophageal Neoplasms therapy
- Abstract
Recurrent esophageal cancer has a poor prognosis.However, we sometimes encounter cases with long-term survival after radical treatment for recurrent esophageal cancer.We perform radical chemoradiotherapy aggressively when recurrent esophageal cancer is present in a limited area and is sufficiently localized to be treated by radiation therapy.From June 2010 to December 2014, 150 patients underwent curative esophagectomy for esophageal cancer.Forty -one cases relapsed and we treated 13 of them with radical chemoradiotherapy.Complete response(CR), non-CR/non-PD, and progressive disease(PD) were observed in 5, 6, and 2 cases, respectively.The CR rate was 38.4%.The median survival time from recurrence was 500± 39.7 days, and the 1-year and 3-year survival rates were 84.6% and 28.7%, respectively. Four out of 5 CR cases were single site recurrences.The other case was multiple and regrowth of the cancer was identified 253 days after the CR.These results suggest that radical chemoradiotherapy for recurrent esophageal cancer after curative esophagectomy can achieve long time survival, especially in cases with single site lymph node recurrence.
- Published
- 2016
11. [A Case of Recurrent Esophageal Cancer Treated with Salvage Lymphadenectomy after Definitive Chemoradiotherapy].
- Author
-
Kano K, Sato T, Maezawa Y, Segami K, Nakajima T, Ikeda K, Hayashi T, Yamada T, Yamamoto N, Oshima T, Yukawa N, Rino Y, Masuda M, Ogata T, Cho H, and Yoshikawa T
- Subjects
- Aged, Carcinoma, Squamous Cell diagnostic imaging, Esophageal Neoplasms diagnostic imaging, Esophageal Squamous Cell Carcinoma, Humans, Lymph Node Excision, Male, Recurrence, Treatment Outcome, Carcinoma, Squamous Cell therapy, Chemoradiotherapy, Esophageal Neoplasms therapy, Salvage Therapy
- Abstract
A 74-year-old man admitted with dysphagia was found to have advanced esophageal squamous cell carcinoma, clinical stage IV (T4N2M0). We initiated definitive chemoradiotherapy(dCRT)with combined 5-fluorouracil and cisplatin chemotherapy( FP therapy)and 50.4 Gy irradiation, followed by boost FP therapy, to which the patient showed confirmed complete response(CR). Local recurrence was detected in the scar of the primary lesion at 4 months after the boost FP therapy. Photodynamic therapy(PDT)for this lesion resulted in CR. Thirteen months later, right hilar and right pericardial lymph node metastases were found. The right hilar lymph node metastases were not visible on CT after triweekly docetaxel therapy, but the pericardial lesions remained. The patient underwent salvage lymphadenectomy without further chemotherapy, and at 5 months after surgery, he was alive and recurrence-free.
- Published
- 2016
12. [Case of Colon Metastasis from Early Gastric Cancer 4 Years after Laparoscopic Assisted Distal Gastrectomy].
- Author
-
Ikeda K, Sato T, Maezawa Y, Kano K, Satoyoshi T, Segami K, Nakajima T, Ogata T, Cho H, and Yoshikawa T
- Subjects
- Adenocarcinoma surgery, Aged, Colectomy, Colon, Ascending surgery, Colonic Neoplasms surgery, Fatal Outcome, Female, Gastrectomy, Humans, Laparoscopy, Stomach Neoplasms surgery, Time Factors, Adenocarcinoma secondary, Colon, Ascending pathology, Colonic Neoplasms secondary, Stomach Neoplasms pathology
- Abstract
A 69-year-old woman who underwent laparoscopic assisted distal gastrectomy for early gastric cancer(pathological T1bN1M0)in June 2011was admitted to the hospital because of abdominal pain in May 2015.A n abdominal CT scan showed ileus caused by a transverse colon tumor and ascending colon perforation.We performed emergency right hemicolectomy and diverting ileostomy.The postoperative pathological findings revealed poorly differentiated adenocarcinoma and signetring cell carcinoma similar to the gastric cancer resected 4 years ago.Immunohistochemical findings showed that the colon tumor was positive for CK7, but negative for CK20 and expressed a gastric mucin phenotype.From these findings, the colon tumor was diagnosed as a metastasis from early gastric cancer.Colon metastasis from early gastric cancer is rare and the diagnosis is difficult in some cases.We herein report this case and discuss the clinical and pathologic features of colon metastasis from gastric cancer.
- Published
- 2016
13. [Three Cases of Adenocarcinoma of the Advanced Esophago-Gastric Junction Confirmed as Pathological Complete Response Following Neoadjuvant Chemotherapyand Gastrectomy].
- Author
-
Sato T, Maezawa Y, Kano K, Segami K, Nakajima T, Ikeda K, Aoyama T, Hayashi T, Yamada T, Oshima T, Rino Y, Masuda M, Ogata T, Cho H, and Yoshikawa T
- Subjects
- Adenocarcinoma diagnostic imaging, Adenocarcinoma surgery, Aged, Antineoplastic Agents therapeutic use, Gastrectomy, Humans, Male, Middle Aged, Neoplasm Invasiveness, Stomach Neoplasms diagnostic imaging, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Tomography, X-Ray Computed, Adenocarcinoma drug therapy, Esophagogastric Junction pathology, Neoadjuvant Therapy, Stomach Neoplasms drug therapy
- Abstract
Neoadjuvant chemotherapy(NAC)is thought to be effective to improve the outcomes in patients with adenocarcinoma of the esophago-gastric junction(AEG). We encountered 3 patients who were confirmed as having a pathological complete response following gastrectomy after NAC. The first patient had Siewert type II and clinical Stage III AEG, the second patient had Siewert type I and clinical Stage III AEG, while the third had Siewert type II and clinical Stage II AEG. Two patients received NAC with 2 courses of S-1 plus cisplatin, while the third patient received 2 courses of docetaxel, S-1, and cisplatin. All of the patients were treated with D2 gastrectomy after the NAC, and remain alive at more than 40 months after initial chemotherapy treatment without recurrence. We report the details of these 3 cases and review the literature.
- Published
- 2016
14. [A Case of HER2-Positive Siewert Type I Adenocarcinoma of the Esophagogastric Junction Treated via Neoadjuvant Chemotherapy Followed by Radical Resection].
- Author
-
Nakajima T, Sato T, Kano K, Maezawa Y, Segami K, Fujikawa H, Ikeda K, Yamada T, Ogata T, Cho H, and Yoshikawa T
- Subjects
- Adenocarcinoma surgery, Capecitabine administration & dosage, Cisplatin administration & dosage, Esophageal Neoplasms pathology, Esophageal Neoplasms surgery, Esophagectomy, Humans, Lymphatic Metastasis, Male, Middle Aged, Trastuzumab administration & dosage, Treatment Outcome, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Esophageal Neoplasms drug therapy, Esophagogastric Junction pathology, Neoadjuvant Therapy
- Abstract
A 63-year-old man with dysphagia was referred to our hospital. He was found to have a type 2 tumor extending from the lower thoracic esophagus to the esophagogastric junction via upper gastrointestinal endoscopy. A biopsy revealed adenocarcinoma with overexpression of the human epidermal growth factor type 2(HER2). The tumor was type I according to Siewert's classification, as the epicenter of the tumor was 27mm to the oral side from the esophago-gastric junction. The clinical diagnosis was T3N1M1, stage IV according to the Japanese Classification of Gastric Carcinoma, and T3N2M0, stage III per the Japanese Classification of Esophageal Cancer. He was treated with neoadjuvant chemotherapy consisting of 6 courses of capecitabine(1,000mg/m / / 2: days 1-14)plus cisplatin(80mg/m2: day 1)and trastuzumab(8mg/kg: day 1 of the first course, 6mg/kg: day 1 after the second course). Computed tomography(CT)and upper gastrointestinal endoscopy showed shrinkage of the primary esophagogastric cancer and lymph node metastases. The patient had a partial response and underwent radical esophagectomy. The pathological findings revealed a T3N2M0, stage III tumor; the tumor was determined to be Grade 1b owing to the chemotherapeutic effect. At a follow-up examination 1 year and 7 months after the start of chemotherapy, the patient is alive without recurrence.
- Published
- 2016
15. [A Case of Long-Term Survival after Gastrectomy and Metachronous Brain Metastasis].
- Author
-
Maezawa Y, Sato T, Kano K, Segami K, Nakajima T, Kawabe T, Shirai J, Fujikawa H, Aoyama T, Hayashi T, Ikeda K, Yamada T, Tsuchida S, Yamamoto N, Ohshima T, Rino Y, Masuda M, Ogata T, Cho H, and Yoshikawa T
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms secondary, Female, Gastrectomy, Humans, Recurrence, Stomach Neoplasms drug therapy, Stomach Neoplasms surgery, Treatment Outcome, Brain Neoplasms drug therapy, Stomach Neoplasms pathology
- Abstract
A30 -year-old woman underwent total gastrectomy with D2 lymph node dissection after being diagnosed with clinical T3, N2, M0, Stage III B gastric cancer. The postoperative pathological findings revealed a T3(SE), N2, M0, Stage III B tumor. Headache, dizziness, and vomiting occurred during chemotherapy for peritoneal recurrence, using weekly paclitaxel on days 1, 8, and 15. Head CT showed a solitary tumor with a diameter of 28mm in the cerebellum, as well as cerebellar swelling and hydrocephalus. She underwent an emergency craniotomy and tumor enucleation. Pathological examination revealed a metastatic brain tumor from the gastric cancer. She received 12 courses of CPT-11 plus cisplatin until discontinuation because of an adverse event. The patient is alive 6 years after the diagnosis of the cerebellar metastasis without recurrence.
- Published
- 2016
16. [A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
- Author
-
Kano K, Sato T, Maezawa Y, Segami K, Nakajima T, Ikeda K, Hayashi T, Yamada T, Yamamoto N, Ohshima T, Yukawa N, Rino Y, Masuda M, Ogata T, Cho H, and Yoshikawa T
- Subjects
- Aged, Chemoradiotherapy, Cisplatin administration & dosage, Docetaxel, Drug Combinations, Esophageal Squamous Cell Carcinoma, Gastrectomy, Humans, Male, Neoplasms, Multiple Primary pathology, Oxonic Acid administration & dosage, Stomach Neoplasms pathology, Taxoids administration & dosage, Tegafur administration & dosage, Adenocarcinoma therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell therapy, Esophageal Neoplasms therapy, Neoplasms, Multiple Primary therapy, Stomach Neoplasms therapy
- Abstract
We report a case of advanced esophageal and gastric cancer that was successfully treated via multimodal therapy. A 65- year-old man with hoarseness was referred to our hospital. He was diagnosed with clinical T4aN2M0, Stage IV esophageal squamous cell carcinoma and clinical T3N1M0, Stage II B gastric adenocarcinoma. He was treated with 3 courses of chemotherapy, administered over 4weeks, with S-1(80mg/m / / 2: day 1-14), cisplatin(60mg/m2: day 1), and docetaxel(40mg/m2: day 1). Computed tomography(CT)revealed shrinkage of the primary esophageal tumor, gastric tumor, and lymph node metastases. Next, we selected definitive radiation chemotherapy(CRT), because lymph node metastases remained around the bilateral recurrent laryngeal nerves. After CRT with a total 60 Gy plus administration of 5-fluorouracil and cisplatin, CT showed that the primary esophageal tumor and lymph node metastases had disappeared. Then, distal gastrectomy was performed for the remaining gastric cancer, as part of the multimodal therapy. After gastrectomy, no systemic chemotherapy was performed. At a follow-up examination 5 years and 6 months after the start of chemotherapy, the patient is alive without recurrence.
- Published
- 2016
17. [Neoadjuvant Chemotherapy for Gastric Cancer].
- Author
-
Yoshikawa T, Sato T, Yamada T, Aoyama T, Ogata T, and Cho H
- Subjects
- Chemotherapy, Adjuvant, Clinical Trials as Topic, Gastrectomy, Humans, Neoplasm Staging, Stomach Neoplasms diagnosis, Stomach Neoplasms surgery, Antineoplastic Agents therapeutic use, Neoadjuvant Therapy, Stomach Neoplasms drug therapy
- Abstract
Adjuvant chemotherapy aims to eradicate residual micro-metastatic tumor cells existing at distant sites outside the surgical field. The current standard adjuvant chemotherapy is S-1 for 1 year or capecitabine plus oxaliplatin for 6 months after D2 gastrectomy. However, there are some rooms in the overall survival of Stage III. Neoadjuvant chemotherapy(NAC)is a promising approach that combines intensive chemotherapy with high compliance; however, it is under development in Japan. Two JCOG phase II trials suggested that NAC was effective for bulky nodal disease. For scirrhous-type malignancy, a JCOG phase III trial is currently ongoing investigating the efficacy of a NAC regimen of S-1 plus CDDP. Another group is conducting 2 randomized phase II trials to compare different regimens and courses of NAC. So far, 2 courses of S-1 plus CDDP or 3 courses of S-1 plus oxaliplatin can be recommended as candidates for the test arm of future phase III studies of NAC.
- Published
- 2016
18. [A Case of HER-2 Positive Advanced Gastric Cancer Responding to Capecitabine+Cisplatin+Trastuzumab Chemotherapy].
- Author
-
Segami K, Sato T, Kawabe T, Hayashi S, Makuuchi Y, Oshima T, Rino Y, Masuda M, Ogata T, Cho H, and Yoshikawa T
- Subjects
- Aged, Cachexia etiology, Capecitabine administration & dosage, Cisplatin administration & dosage, Female, Gastrectomy, Humans, Neoadjuvant Therapy, Receptor, ErbB-2 analysis, Stomach Neoplasms complications, Stomach Neoplasms drug therapy, Stomach Neoplasms surgery, Trastuzumab administration & dosage, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms pathology
- Abstract
A 67-year-old woman was referred to our hospital for type 1 gastric cancer. We diagnosed the patient with advanced gastric cancer (tub2>por, HER2-positive), and the clinical findings were T4aN1M1 (lung), Stage Ⅳ. The patient had cancer cachexia. As first-line chemotherapy, a regimen consisting of capecitabine (X) (1,600 mg/m2/day, days 1-14), cisplatin (P) (60 mg/m2/day, day 1), and trastuzumab (H) (8 mg/kg/day>6 mg/kg/day, day 1) was administered every 3 weeks and repeated 6 times. After receiving 6 courses, the patient's general condition and cancer cachexia symptoms improved. The size of the primary lesion significantly decreased, and lung metastasis was not visible on a PET scan. Simultaneously, a new 0-Ⅱc tumor was detected in the cardia, and a biopsy revealed a malignant lymphoma. Total gastrectomy and D2 lymph node dissection without splenectomy were performed. The final diagnosis was T4aN0M0. After treatment, the tumor was histologically evaluated as Grade 1b, and the remnant cancer cells were found to be HER2-negative (loss of HER2). The patient has been alive for 5 months and is receiving adjuvant chemotherapy comprising capecitabine and trastuzumab. Following chemotherapy containing trastuzumab, the patient with cachexia who was diagnosed with unresectable HER2-positive advanced gastric cancer showed improvement in the cachexia symptoms and the disappearance of lung metastasis.
- Published
- 2015
19. [The case of a solitary pulmonary tumor which could be diagnosed as early gastric cancer recurrence by detailed pathological examinations].
- Author
-
Hayashi S, Sato T, Yokose T, Ito H, Nakayama H, Segami K, Kawabe T, Aoyama T, Makuuchi Y, Oshima T, Rino Y, Masuda M, Ogata T, Cho H, and Yoshikawa T
- Subjects
- Gastrectomy, Humans, Male, Middle Aged, Multimodal Imaging, Pneumonectomy, Positron-Emission Tomography, Recurrence, Stomach Neoplasms surgery, Tomography, X-Ray Computed, Adenocarcinoma diagnostic imaging, Adenocarcinoma secondary, Adenocarcinoma surgery, Lung Neoplasms diagnostic imaging, Lung Neoplasms secondary, Lung Neoplasms surgery, Stomach Neoplasms pathology
- Abstract
We report the case of a solitary pulmonary tumor, which was diagnosed as recurrent early gastric cancer by detailed pathological examinations. A 59-year old man initially underwent total gastrectomy for gastric adenocarcinoma located at the esophago-gastric junction. A pathological examination indicated a papillary adenocarcinoma (pap ) that had invaded the submucosal layer (sm²), but had not metastasized to the regional lymph nodes (n0). The final diagnosis was P0H0M0T1bN0, Stage IA. Chest computed tomography (CT) 30 months after primary surgery indicated a solitary tumor with a diameter of 9 mm at S3 of the left lung. A positron emission tomography (PET)-CT scan showed an accumulation of ¹⁸F-fluordeoxy-glucose (FDG18) at the same location. Lung cancer was suspected and the patient was given a left upper lobectomy. The resected tumor was diagnosed as gastric cancer metastatic adenocarcinoma by permanent pathological examination. The tumors showed similar histology and immuno histochemical findings for CK7, CK20, TTF-1, SP-A, CDX-2, and HER2 . Early gastric cancer is an almost curable disease and recurrence is very rare. We report the details of this case and review the literature.
- Published
- 2014
20. [Pneumothorax after treatment with bevacizumab-containing chemotherapy for breast cancer - a case report].
- Author
-
Makino T, Kudo S, and Ogata T
- Subjects
- Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab, Breast Neoplasms diagnostic imaging, Female, Humans, Middle Aged, Paclitaxel administration & dosage, Pneumothorax therapy, Radionuclide Imaging, Tomography, X-Ray Computed, Antibodies, Monoclonal, Humanized adverse effects, Breast Neoplasms drug therapy, Pneumothorax chemically induced
- Abstract
A 62-year-old woman presented with a right breast tumor. Examination yielded a diagnosis of right breast cancer (T4bN3bM1[lung]). After right breast mastectomy for local control, 9 sessions of chemotherapy containing an anthracycline and taxane were administered. Because of progression of lung metastasis, bevacizumab and paclitaxel were administered. Follow-up computed tomography(CT)scans showed that the multiple solid lung metastases had reduced in size, but a hollowing effect was noted. Eight months later, the patient developed left pneumothorax. The origin of the pneumothorax was unclear, but the hollowing due to the lung metastases seen after bevacizumab treatment was thought to be the cause. The pneumothorax resolved after tube thoracostomy, but disease progression occurred because of the lack of chemotherapy, and the patient's general condition worsened. Although rare, we speculate that there is a risk of pneumothorax after bevacizumab- containing chemotherapy.
- Published
- 2014
21. [A case of rectal stenosis due to peritoneal dissemination from gastric cancer that was treated with chemoradiation therapy].
- Author
-
Shirai J, Cho H, Fujikawa H, Iwasaki K, Ogata T, Yoshikawa T, Tsuburaya A, Sujishi K, Yamada T, Osaragi T, Yoneyama K, Kasahara A, Yamamoto Y, Rino Y, and Masuda M
- Subjects
- Aged, 80 and over, Antimetabolites, Antineoplastic therapeutic use, Antineoplastic Agents, Phytogenic therapeutic use, Constriction, Pathologic etiology, Drug Combinations, Humans, Male, Oxonic Acid therapeutic use, Paclitaxel therapeutic use, Peritoneal Neoplasms secondary, Stomach Neoplasms pathology, Tegafur therapeutic use, Chemoradiotherapy, Peritoneal Neoplasms therapy, Rectal Diseases etiology, Stomach Neoplasms therapy
- Abstract
An 82-year-old man underwent total gastrectomy(D2 lymph node dissection)in August 2006. The pathological findings indicated T4a, N3, M0, Stage IIIC gastric cancer, but adjuvant chemotherapy was not initiated. In October 2009, he presented to the hospital with dyschezia. During colonoscopy, the scope could not pass through the colon, thus indicating rectal stenosis. The biopsy findings indicated the presence of signet ring cell carcinoma, which was determined to be due to the peritoneal dissemination from the gastric cancer. To avoid the need for creating a stoma, radiation therapy(2 Gy×20; total dose, 40 Gy)and chemotherapy(weekly paclitaxel and S-1)were initiated. Rectal stenosis was improved and complete remission was maintained until May 2013.
- Published
- 2013
22. [A case of primary esophageal carcinoma treated with 5-fluorouracil plus cisplatin and curatively resected after complete response].
- Author
-
Iwasaki K, Ogata T, Fujikawa H, Shirai J, Cho H, Yoshikawa T, Ohta Y, Tachibana S, Oosaka Y, and Tsuchida A
- Subjects
- Aged, Carcinoma, Squamous Cell surgery, Cisplatin administration & dosage, Esophageal Neoplasms pathology, Esophageal Neoplasms surgery, Female, Fluorouracil administration & dosage, Humans, Remission Induction, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell drug therapy, Esophageal Neoplasms drug therapy, Neoadjuvant Therapy
- Abstract
A 76-year-old woman visited the hospital for difficulty during swallowing. Endoscopy revealed the presence of an esophageal tumor, and she was referred to our hospital for further examination. A subsequent endoscopy revealed a whole rounded type 3 tumor in the lower esophagus. Computed tomography( CT) scan showed swelling of the lymph node( number 106recL), and no remote metastasis was observed. A diagnosis of Lt type 3, T3N1M0, clinical Stage III esophageal cancer was made, and neoadjuvant chemotherapy( NAC) with 5-fluorouraci(l 5-FU) plus cisplatin( CDDP) was administered. The only side effect noted was grade 1 anorexia. Endoscopy after 2 courses of NAC revealed only scars, and no tumor was detected. CT showed remarkable reduction of the lymph nodes and esophageal wall thickness. Subtotal esophagectomy by right thoracotomy, retrosternal gastric tube reconstruction, and 3-field lymph node dissection were performed. Histopathological examination of the resected specimen revealed the absence of malignant cells in the esophagus and presence of metastasis in the lymph node (Effect 3). Although we have encountered 49 cases of esophageal cancer treated with NAC at our center, this was the first case in which pathologically complete response was achieved. Here, we report a rare case of esophageal carcinoma, which was curatively resected after complete response was achieved following treatment with 5-FU/CDDP as NAC.
- Published
- 2013
23. [Effect of enteral nutrition enriched with eicosapentaenoic acid on body weight loss and compliance with S-1 adjuvant chemotherapy after gastric cancer surgery].
- Author
-
Aoyama T, Hayashi T, Fujikawa H, Ogata T, Cho H, Wada H, Kitani Y, Yukawa N, Oshima T, Rino Y, Ozawa Y, Masuda M, and Yoshikawa T
- Subjects
- Chemotherapy, Adjuvant adverse effects, Drug Combinations, Female, Humans, Male, Middle Aged, Oxonic Acid therapeutic use, Stomach Neoplasms surgery, Tegafur therapeutic use, Eicosapentaenoic Acid therapeutic use, Enteral Nutrition, Gastrectomy adverse effects, Oxonic Acid adverse effects, Stomach Neoplasms drug therapy, Tegafur adverse effects, Weight Loss
- Abstract
Background: Eicosapentaenoic acid-enriched oral nutritional supplements (Prosure®; Abbott Japan, Tokyo, Japan) may attenuate surgical stress and catabolism after gastric cancer surgery. The present study aimed to evaluate the effects of Prosure® on body weight loss( BWL) and compliance with S-1 adjuvant chemotherapy after gastrectomy., Patients and Methods: Patients who underwent curative total gastrectomy for gastric cancer were selected to undergo adjuvant S-1 chemotherapy at Kanagawa Cancer Center between December 2010 and October 2011. The patients received a normal postgastrectomy diet and two 240 mL packs of Prosure® for 21 postoperative days. BWL was defined as %BWL and calculated as %BWL=(preoperative body weight-1-month postoperative body weight)×100/preoperative body weight. Time to S-1 treatment failure was calculated., Results: Five patients were enrolled in this study. The median age was 62.0 years. One patient was male, and 4 were female. The 1-month postoperative BWL was 92.1%. Compared to our previous report, a 20% risk reduction was observed in this study (Prosure® group vs control group, 92.1% vs 89.7%). Moreover, all the patients continued with the S-1 adjuvant chemotherapy for longer than 6 months., Conclusion: Prosure® may inhibit BWL at 1 month after gastrectomy. Moreover, Prosure® improved the patients' compliance with the adjuvant chemotherapy after gastrectomy.
- Published
- 2013
24. [A case of gastric cancer with intensive peritoneal dissemination treated with long-term chemotherapy and surgery].
- Author
-
Shirai J, Cho H, Fujikawa H, Iwasaki K, Ogata T, Yoshikawa T, Tsuburaya A, Sujishi K, Yamada T, Osaragi T, Yoneyama K, Kasahara A, Yamamoto Y, Rino Y, and Masuda M
- Subjects
- Combined Modality Therapy, Docetaxel, Drug Combinations, Fatal Outcome, Humans, Lymphatic Metastasis, Male, Middle Aged, Oxonic Acid administration & dosage, Peritoneal Neoplasms secondary, Peritoneal Neoplasms surgery, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Taxoids administration & dosage, Tegafur administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Peritoneal Neoplasms drug therapy, Salvage Therapy, Stomach Neoplasms drug therapy
- Abstract
A 45-year-old man was transferred to our hospital because of advanced gastric cancer and peritoneal dissemination. After he received an S-1 plus cisplatin( CDDP) regimen for 6 courses, the primary lesion and ascites had disappeared. However, the primary lesion recurred, and he underwent treatment with 16 courses of an S-1 plus docetaxel regimen. He subsequently developed peripheral neuropathy, and was switched to the irinotecan (CPT-11) regimen. As he experienced appetite loss, it was impossible to continue the chemotherapy. Therefore, he underwent a salvage surgery and an R0 resection was performed. However, 9 months after the surgery, he experienced paraaortic lymph node recurrence and peritoneal dissemination. The patient died 13 months after the surgery.
- Published
- 2013
25. [Safety and feasibility of gastrectomy after neoadjuvant chemotherapy for gastric cancer].
- Author
-
Aoyama T, Hayashi T, Fujikawa H, Ogata T, Cho H, Wada H, Kitani Y, Yukawa N, Oshima T, Rino Y, Ozawa Y, Masuda M, and Yoshikawa T
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Female, Humans, Male, Middle Aged, Stomach Neoplasms drug therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gastrectomy adverse effects, Neoadjuvant Therapy, Postoperative Complications, Stomach Neoplasms surgery
- Abstract
Purpose: The aim of this study was to evaluate the safety and feasibility of gastrectomy after neoadjuvant chemotherapy in patients with gastric cancer., Patients and Methods: Forty-five patients received neoadjuvant chemotherapy and curative gastrectomy between December 2002 and May 2011. Surgical complications were evaluated according to the Clavien- Dindo classification., Result: The median age of the patients was 63 years. Twenty-three patients received a PTX and CDDP regimen, 20 received an S-1 and CDDP regimen, 1 received an S-1 regimen, and 1 received an CPT-11 and CDDP regimen as neoadjuvant chemotherapy. Distal gastrectomy was performed in 6 patients, and total gastrectomy was performed in 39 patients. The median operation time was 268 minutes, and the median blood loss was 249.5 mL. Complications more severe than grade 2 were observed in 10 patients: anatomic bleeding( grade 3a) was observed in 2 patients; abdominal abscess( grade 2), in 1 patient; and pancreatic fistula( grade 2), in 7 patients. No surgical mortality was observed., Discussion: The results of our study suggest that gastrectomy after neoadjuvant chemotherapy for the treatment of patients with gastric cancer is safe and feasible.
- Published
- 2013
26. [Clinical significance of the human epidermal growth factor receptor 2( HER2) in patients with recurrent gastric cancer who received S-1 adjuvant chemotherapy].
- Author
-
Aoyama T, Hayashi T, Fujikawa H, Ogata T, Cho H, Wada H, Kitani Y, Yukawa N, Oshima T, Rino Y, Ozawa Y, Masuda M, and Yoshikawa T
- Subjects
- Adult, Aged, Aged, 80 and over, Chemotherapy, Adjuvant, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Staging, Recurrence, Stomach Neoplasms chemistry, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Antimetabolites, Antineoplastic therapeutic use, Oxonic Acid therapeutic use, Receptor, ErbB-2 analysis, Stomach Neoplasms drug therapy, Tegafur therapeutic use
- Abstract
Purpose: The aim of this study was to clarify the human epidermal growth factor receptor 2( HER2) positivity, clinicopathological characteristics, and survival of patients with recurrent HER2-positive gastric cancer who received S-1 adjuvant chemotherapy., Methods: Thirty-eight patients with recurrent gastric cancer who underwent curative D2 surgery and received S-1 adjuvant chemotherapy between June 2002 and December 2011 were examined. HER2 positivity was determined as defined in the ToGA study., Results: The positivity score was assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) as follows: IHC 0 in 27 patients, IHC 1+in 4, IHC 2+/FISH-in 3, IHC 2+/FISH+in 1, and IHC 3+in 3. The HER2 positivity rate was 10.5% (4/38). HER2-positive recurrent gastric cancer was characterized by a differentiated histological feature and frequent blood vessel invasion. However, the recurrence and survival rates were not significantly different between the HER2-negative and HER2-positive tumors., Conclusions: The HER2 positivity rate after S-1 adjuvant chemotherapy did not differ significantly between patients with recurrent gastric cancer and those with primary Stage II/III gastric cancer, suggesting that S-1 adjuvant chemotherapy was equally effective, regardless of HER2 status.
- Published
- 2013
27. [A case of gastric small cell carcinoma with metastatic liver tumors responding to surgery and chemotherapy].
- Author
-
Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Hasegawa S, Tsuchida K, Ogata T, Cho H, Yukawa N, Oshima T, Rino Y, Ozawa Y, Kitani Y, Wada H, Masuda M, and Tsuburaya A
- Subjects
- Aged, Carcinoma, Small Cell secondary, Carcinoma, Small Cell surgery, Combined Modality Therapy, Humans, Liver Neoplasms secondary, Male, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Antineoplastic Agents therapeutic use, Carcinoma, Small Cell drug therapy, Liver Neoplasms drug therapy, Stomach Neoplasms drug therapy
- Abstract
We report a case of gastric small cell carcinoma with metastatic liver tumors responding to surgery and chemotherapy. The patient was a 67-year-old man with advanced gastric cancer, clinically diagnosed as P0H1M0CY0T3N1. He was registered in a phase III trial, and was scheduled to undergo gastrectomy and S-1 plus CDDP chemotherapy after surgery. He underwent D1 total gastrectomy and Roux-en-Y reconstruction. Small cell carcinoma of the stomach was diagnosed from the histopathological findings. After surgery, he received the following chemotherapy: 13 courses of CPT-11 plus CDDP chemotherapy, 2 courses of S-1, 5 courses of paclitaxel, and 6 courses of CPT-11. The patient is alive 22 months after his operation. We conclude that the combination of surgery and chemotherapy was effective for small cell carcinoma of the stomach, which was considered to have a poor prognosis.
- Published
- 2012
28. [Comparison of body weight loss in gastrectomy patients who underwent only surgery and those who underwent surgery followed up with S-1 adjuvant chemotherapy].
- Author
-
Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Ogata T, Cho H, Yukawa N, Oshima T, Rino Y, Ozawa Y, Kitani Y, Wada H, Masuda M, and Tsuburaya A
- Subjects
- Aged, Chemotherapy, Adjuvant, Drug Combinations, Humans, Middle Aged, Stomach Neoplasms surgery, Antimetabolites, Antineoplastic therapeutic use, Gastrectomy, Oxonic Acid therapeutic use, Stomach Neoplasms drug therapy, Tegafur therapeutic use, Weight Loss
- Abstract
Background: Body weight loss is a common outcome in patients with gastric cancer who have undergone gastrectomy. However, the rate of body weight loss after surgery is unknown., Methods: In this retrospective study, we selected patients who underwent radical gastrectomy for gastric cancer and were diagnosed with Stage II or III disease. Further, we compared the body weight loss after surgery between patients in the surgery alone group and the S-1 adjuvant chemotherapy group., Results: We evaluated 163 patients, of which 81 underwent only surgery, and 82 underwent surgery followed up with S-1 adjuvant chemotherapy. The body weight loss rate at 1, 3, and 6 months in the surgery alone group were 93.1%, 92.9%, and 94.9%, while those in the S-1 adjuvant group were 92.9%, 90.4%,and 91.9%, which was a significant difference., Conclusions: Body weight loss after gastrectomy was higher in the S-1 adjuvant group than in the surgery alone group. Further, nutritional support is required for these patients to maintain body weight after surgery.
- Published
- 2012
29. [Case of stage IIB gastric cancer with positive margin treated with sequential therapy consisting of S-1, chemoradiation therapy with paclitaxel and CDDP, and S-1 after surgery].
- Author
-
Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Hasegawa S, Tsuchida K, Ogata T, Cho H, Yukawa N, Oshima T, Rino Y, Ozawa Y, Kitani Y, Wada H, Masuda M, and Tsuburaya A
- Subjects
- Adult, Chemoradiotherapy, Cisplatin administration & dosage, Drug Combinations, Humans, Male, Neoplasm Staging, Oxonic Acid administration & dosage, Paclitaxel administration & dosage, Stomach Neoplasms pathology, Tegafur administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms therapy
- Abstract
The patient was a 31-year-old man with advanced gastric cancer, clinically diagnosed as ML, Less, Type 3, sig, cT3, cN0, cH0, cP0, cM0, cCY0, cStage IIA. He underwent D2 distal gastrectomy. On microscopic examination, tumor cells were detected in the distal margin of the resected stomach. After surgery, he received 1 course of S-1 followed by chemoradiation therapy(1.8 Gy×25, a total of 45 Gy) with 90 mg/m2 of paclitaxel and 40 mg/m2 of CDDP on days 1, 15, and 29 over 5 weeks. Subsequently, he received 5 cycles of S-1 chemotherapy. To date, no recurrence has been observed 5 years after surgery. This sequential therapy is an option to consider for enabling local and systemic control after gastric cancer surgery.
- Published
- 2012
30. [Postoperative anastomotic hemorrhage after gastrectomy].
- Author
-
Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Hasegawa S, Tsuchida K, Ogata T, Cho H, Yukawa N, Oshima T, Rino Y, Ozawa Y, Kitani Y, Wada H, Masuda M, and Tsuburaya A
- Subjects
- Aged, Anastomosis, Surgical adverse effects, Humans, Male, Middle Aged, Postoperative Hemorrhage therapy, Gastrectomy adverse effects, Postoperative Hemorrhage etiology, Stomach Neoplasms surgery
- Abstract
Background: Postoperative anastomotic hemorrhage is a relatively rare complication. However, when it does occur, immediate treatment is needed., Methods: In all, 1,700 patients underwent curative gastrectomy between 2000 and 2010. Anastomotic hemorrhage was observed in 9 patients after surgery. The clinical course of these 9 patients was analyzed., Results: The median age of the patients was 62 years, and all patients were men. Two patients underwent distal gastrectomy, 1 underwent laparoscopic distal gastrectomy, and 6 underwent total gastrectomy. Bleeding occurred as follows: 5 were at gastro- or esophagojejunostomic site, 2 were at gastroduodenostomic site, and 2 were at jejunojejunostomic site. Five patients received conservative treatment and 2 underwent re-operation. Two additional patients achieved complete hemostasis with endoscopic treatment. The patients who received endoscopic treatment were discharged earlier than those who received other treatments., Conclusions: Endoscopic intervention was useful for the diagnosis and treatment of postoperative anastomotic hemorrhage.
- Published
- 2012
31. [Neoadjuvant chemotherapy for gastric cancer--evidence from the world and future strategy in Japan].
- Author
-
Yoshikawa T, Aoyama T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, Cho H, and Tsuburaya A
- Subjects
- Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Humans, Neoadjuvant Therapy, Stomach Neoplasms therapy
- Abstract
Adjuvant chemotherapy is aimed at eradicating residual micro-metastatic tumor cells existing at the distant site outside of the surgical field. From evidence gathered from around the world, several courses of intensive neoadjuvant chemotherapy are promising even in Japan, where D2 surgery is the standard for local control. The Japan Clinical Oncology Group (JCOG) plays a central role in the development of neoadjuvant chemotherapy in Japan. Two JCOG Phase II trials clarified that neoadjuvant chemotherapy was effective for bulky nodal disease. A JCOG Phase III is now on-going to confirm the efficacy of neoadjuvant chemotherapy of S-1+CDDP for cancer of the schirrhous type. In another group, two randomized Phase II trials are also ongoing to compare different regimens and courses of neoadjuvant chemotherapy. These studies will set the direction of neoadjuvant chemotherapy development in the future.
- Published
- 2012
32. [A case of esophageal cancer with intramural metastasis demonstrates a good clinical course after induction chemotherapy followed by chemoradiation].
- Author
-
Yoshii T, Ohkawa S, Watanabe T, Ogata T, and Kitamura T
- Subjects
- Carcinoma, Squamous Cell pathology, Chemoradiotherapy, Esophageal Neoplasms pathology, Humans, Induction Chemotherapy, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Positron-Emission Tomography, Tomography, X-Ray Computed, Carcinoma, Squamous Cell therapy, Esophageal Neoplasms therapy
- Abstract
A 63-year-old man with dysphagia visited our hospital in February 2007. Esophagogastroduodenoscopy and computed tomography revealed that he suffered from advanced esophageal cancer with intramural metastasis at clinical stage III (T3N1). The patient underwent induction chemotherapy because he had great difficulty deciding which treatment would be more beneficial for him use dash surgery or chemoradiation. The reason for his in decision was that esophageal cancer with intramural metastasis is known to have a poor prognosis after surgery, and although chemoradiation is the more attractive therapy that avoids invasive surgery, it is very difficult to predict a response. Currently, he has survived for more than 3 years with no recurrence, after chemoradiation that followed a good response to induction chemotherapy. This result suggested that induction chemotherapy followed by chemoradiation can be one of the useful strategies for patients who have esophageal cancer with a negative prognosis factor for surgery, such as intramural metastasis.
- Published
- 2011
33. [S-1/krestin immunochemotherapy for patients with advanced gastric cancer].
- Author
-
Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, Cho H, Tsuburaya A, Rino Y, and Masuda M
- Subjects
- Adult, Drug Combinations, Female, Humans, Male, Middle Aged, Oxonic Acid administration & dosage, Proteoglycans administration & dosage, Stomach Neoplasms immunology, Stomach Neoplasms pathology, Tegafur administration & dosage, Immunotherapy, Oxonic Acid therapeutic use, Proteoglycans therapeutic use, Stomach Neoplasms therapy, Tegafur therapeutic use
- Abstract
Background: S-1 mono-therapy for advanced gastric cancer is hard to continue in some patients due to adverse events. We retrospectively examined the patients who received S-1/Krestin( PSK) immunochemotherapy for advanced gastric cancer., Methods: During September 2006 to August 2008, 3 patients had received S-1/PSK. S-1 was given for 6-week schedule or 3-week schedule, and PSK was for everyday during the S-1 treatment., Results: Cases 1 and 2 had lymph node metastases after surgery. Case 3 had peritoneal metastasis. The median treatment duration was 112 days. The median overall survival was 552 days. All patients stopped the treatment due to progression of disease. There were no patients who stopped the treatment due to adverse events., Conclusions: PSK may increase the compliance of S-1.
- Published
- 2011
34. [Prognosis and clinical course of gastric cancer with para-aortic lymph node metastasis after curative D2 gastrectomy and adjuvant chemotherapy with S-1].
- Author
-
Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, Cho H, Tsuburaya A, Rino Y, and Masuda M
- Subjects
- Aged, Aorta, Combined Modality Therapy, Drug Combinations, Female, Gastrectomy, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Prognosis, Stomach Neoplasms drug therapy, Stomach Neoplasms surgery, Antimetabolites, Antineoplastic therapeutic use, Oxonic Acid therapeutic use, Stomach Neoplasms pathology, Tegafur therapeutic use
- Abstract
Background: Survival and clinical course were unknown in patients with recurrence of para-aortic lymph node after curative D2 gastrectomy and adjuvant S-1 chemotherapy., Methods: The study examined clinical characteristics and prognosis of 3 patients who had para-aortic nodal recurrence after curative D2 gastrectomy and S-1 adjuvant chemotherapy., Results: Initial stage was III C in all of the patients. Median treatment interval of S-1 was 8 . 8 months. Para-aortic nodal metastasis was single in 2 and multiple in 1 patient. Median survival time was 14 .3 months. Other recurrent sites than para- aortic node were not seen in all of the patients., Conclusions: In the times of S-1 adjuvant chemotherapy, it is valuable to know whether para-aortic node should be resected prophylactically, or be treated after recurrence, or be treated by locally or systemically.
- Published
- 2011
35. [Assessment of the cost of laparoscopy-assisted gastrectomy].
- Author
-
Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, Cho H, Tsuburaya A, Ito M, Ohta Y, Kabe Y, Suzuki C, Rino Y, and Masuda M
- Subjects
- Humans, Stomach Neoplasms surgery, Gastrectomy economics, Laparoscopy economics, Stomach Neoplasms economics
- Abstract
Background: The cost of laparoscopic gastrectomy (LG) has not been fully clarified yet., Patients and Methods: The actual cost for the instruments used for surgery was examined between LG and conventional open gastrectomy( OG) by separating distant (l D-) and total (l T-) gastrectomy in a total of 20 patients(5 for each)during Oct 2010 and Feb 2011. The profit was defined as the difference of the actual cost and the operation fee including the instruments determined by the insurance and compared., Results: The fee for D-OG, T-OG, D-LG, and T-LG were 708, 700 yen, 856 , 400 yen, 783 , 600 yen and 922 , 300 yen, respectively. The mean profits of D-OG, T-OG, D-LG, and T-LG were 408 , 297 yen, 475 , 812 yen, 308, 681 yen and 269 , 478 yen, respectively., Conclusion: Appropriate surgical and instrumental fees should be determined considering the actual cost.
- Published
- 2011
36. [More than 20 years of long-term survival case of intraabdominal GIST by combined therapies with frequent surgeries].
- Author
-
Katayanagi S, Katsumata K, Murakoshi Y, Ogata T, Serizawa H, Tsuchida A, Aoki T, and Shimazu M
- Subjects
- Benzamides, Combined Modality Therapy, Female, Gastrointestinal Stromal Tumors mortality, Humans, Imatinib Mesylate, Middle Aged, Reoperation, Antineoplastic Agents administration & dosage, Gastrointestinal Stromal Tumors therapy, Piperazines administration & dosage, Pyrimidines administration & dosage
- Abstract
A jejunum partial resection was performed on a 49-year-old female for jejunum leiomyosarcoma of 7 cm in 1990. She was resected four times for recurrent tumors from 1993 to 2004. We started an internal use of imatinib in 2003, because we could get a diagnosis of GIST. After the surgery of 2004, she stopped taking the internal use of imatinib, but an intraabdominal recurrence occurred in 2006 and she restarted taking the internal use of imatinib.
- Published
- 2010
37. [Laparoscopic radiofrequency ablation for hepatocellular carcinoma].
- Author
-
Kitasato Y, Yasunaga M, Goto Y, Sato T, Akasu G, Shiota K, Sakai H, Ogata T, Okuda K, Kinoshita H, Shirouzu K, and Aoyagi S
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Postoperative Complications, Treatment Outcome, Carcinoma, Hepatocellular surgery, Catheter Ablation methods, Laparoscopy, Liver Neoplasms surgery
- Abstract
We examined the case of laparoscopic radiofrequency ablation (L-RFA) to hepatocellular carcinoma (HCC), and then the method of this treatment was considered in terms of selection and adjustment. Between January 2008 and May 2010, L-RFC was performed on 18 cases (27 tumors). A total operation time was 203 minutes (± 85.5). The median survival time was 562 days (± 197 day). The amount of blood was 21.0 g (± 68.4), and 3 postoperative complications (pleural effusion) were observed. The average length of hospital stay after the operation was 8 days. There was no vestigial remnant in all cases after the operation. The prognosis of death due to a liver failure was one case on the 516th day after the operation. All other 17 cases were survived. If the tumors were identified by the naked eye and ultrasonography, and considering the position in relation to the main vas, the ablation would be possible for the troublesome part in case of the percutaneous approach. Therefore, we thought the application of RFA to HCC would be more expandable.
- Published
- 2010
38. [Role of surgical resection for scirrhous gastric cancer with minimal peritoneal metastasis].
- Author
-
Yoshikawa T, Aoyama T, Watanabe T, Hayashi T, Ogata T, Cho H, Tsuburaya A, and Kobayashi O
- Subjects
- Adenocarcinoma, Scirrhous mortality, Adenocarcinoma, Scirrhous pathology, Humans, Proportional Hazards Models, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Adenocarcinoma, Scirrhous surgery, Peritoneal Neoplasms secondary, Stomach Neoplasms surgery
- Abstract
Prognosis of scirrhous gastric cancer with minimal peritoneal metastasis was poor, and the role of resection has not been clarified yet. Analysis 1: Overall survival was examined in 79 patients who underwent R0/R1 resection during 1970-1995 at Kanagawa Cancer Center (Group A), and in 47 patients who underwent R0/R1 resection and received S1 chemotherapy at the 30 hospitals of Japan Clinical Oncology Group (Group B). Hazard ratio (HR) of group B to group A was examined. HR was 0.64 at 1 year, 0.76 at 2-year, and 0.92 at 3-year. Analysis 2: HR of S1 group in SPIRITS phase III trial to FU group in JCOG 9205 phase III trial was examined. HR was 0.64 at 1 year and 0.84 at 2-year. Analysis 3: HR was compared each other including HR of ACTS-GC phase III trial. HR was ACTS
- Published
- 2010
39. [A case of type 4 advanced gastric cancer treated by S-1 simple suspension method with CDDP].
- Author
-
Ito K, Ogata T, Katayanagi S, Nomura T, Ishizaki T, Yasuda Y, Sonoda I, Suzuki Y, Sumi T, Tsuchida A, Aoki T, and Shimazu M
- Subjects
- Aged, Constriction, Pathologic, Drug Combinations, Female, Humans, Quality of Life, Stomach Neoplasms pathology, Suspensions, Antimetabolites, Antineoplastic administration & dosage, Antineoplastic Agents administration & dosage, Cisplatin administration & dosage, Oxonic Acid administration & dosage, Stomach Neoplasms drug therapy, Tegafur administration & dosage
- Abstract
S-1 is a key drug for advanced, recurrent gastric cancer. It is difficult to administer S-1 for inoperable gastric cancer with stenosis. We report that a simple suspension method allows administration of S-1 for improved quality of life. The patient was a 65-year-old woman. She consulted a doctor regarding her poor food intake, and had a medical examination with chest-abdominal CT and gastrofiberscopy. She was diagnosed as type 4 gastric cancer with esophageal invasion. It was difficult for her to drink a cup of water due to the stenosis, but we could insert a 6 Fr-Elemental Diet (ED) tube into her stomach. S-1 was dissolved by the simple suspension method. She received combination chemotherapy of S-1 100mg/body (day 1-21) and CDDP 80 mg/body (day 8). After two courses, her intake was much improved; she was able to eat rice porridge and was discharged with improved quality of life. S-1 suspension with ED tube was effective for advanced gastric cancer with stenosis.
- Published
- 2010
40. [S-1 activity in non-small cell lung cancer in clinical practice].
- Author
-
Inagaki M, Onuki T, Iguchi K, Ogata T, Hayashi Y, Saito K, Wakai Y, Takabe K, Shinohara Y, Suzuki K, Ohtani T, and Horikoshi K
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Disease Progression, Drug Combinations, Female, Humans, Lung Neoplasms genetics, Lung Neoplasms metabolism, Lung Neoplasms pathology, Male, Middle Aged, Oxonic Acid adverse effects, Oxonic Acid pharmacology, Survival Rate, Tegafur adverse effects, Tegafur pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Oxonic Acid therapeutic use, Tegafur therapeutic use
- Abstract
Objective: We evaluated retrospectively single-agent S-1 chemotherapy in non-small cell lung cancer patients in clinical practice., Methods: Sixteen consecutive patients treated with single-agent S-1 for NSCLC between July 2005 and June 2007 at the Department of Thoracic Surgery, Tsuchiura Kyodo General Hospital. The treatment schedule comprised oral administration of S-1 at 80-120 mg/day. One cycle of S-1 consisted of consecutive administration to 14 (10 cases)or 28(6 cases)days followed by a 14-day rest., Results: Patients profiles were: M/F: 11/5, median age 68 years old(range 51-83), PS 0/1/2/3: 2/6/5/3, adeno/squamous/large: 13/2/1, clinical stage 3A/3B/4: 3/4/9, prior chemotherapy regimens 0/1/2/3/4: 2/3/4/5/2, prior surgery/radiation: 12/5 were performed. Median number of delivered cycles was 5 cycles(range 1-13). Grade 3 hematological toxicities were anemia(6%)and thrombocytopenia(6%). Grade 3 non-hematological toxicities were nausea(6%)and vomiting(6%). Response of 13 patients could be evaluated after 2-4 cycles of S-1. Four partial responses were observed, for a response rate of 31%. The survival time was 67-852 days(average 14.0 months), 1-year survival rate was 74.0%, median time to progression was 4.6 m, and 1- year progression free survival was 25.0%., Conclusion: Single-agent S-1 chemotherapy has modest activity and is the one of the important regimens and tolerable for elderly, poor-PS, recurrent patients with NSCLC in clinical practice.
- Published
- 2009
41. [Verification of CTL assay and DTH used in monitoring of peptide-pulsed dendritic cell therapy].
- Author
-
Iwadate M, Kanazawa M, Satou Y, Monma T, Sassa M, Suzuki S, Endoh Y, Nakamura I, Ohki S, Sekikawa K, Takenoshita S, Takagi T, Irisawa A, Oohira H, Ogata T, and Ohto H
- Subjects
- Aged, Aged, 80 and over, Cells, Cultured, Dendritic Cells cytology, Female, Humans, Injections, Subcutaneous, Lymphocyte Count, Male, Middle Aged, Neoplasms blood, Neoplasms immunology, Neoplasms pathology, Neoplasms therapy, Reproducibility of Results, Skin Tests, T-Lymphocytes, Cytotoxic cytology, Carcinoembryonic Antigen blood, Dendritic Cells immunology, Dendritic Cells transplantation, Hypersensitivity, Delayed immunology, Immunotherapy, Peptide Fragments immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
CTL assay and DTH used in monitoring cases of peptide-pulsed DC subcutaneous vaccination therapy (with high value of serum CEA by HLA2402) using CEA652 (9) that carried out at our facilities were verified. One out of 10 cases (10%) was SD, and 3 out of 10 cases were the induction of the CTL precursor observed for CTL assay in the peripheral blood of patients after the completion of 1 cycle (administered three times). In 2 cases, positive conversion was observed for DTH reaction. For the SD case, both CTL induction and positive conversion for DTH was observed. A reduction of the CEA value was observed in 3 patients among the 9 cases of PD. While the usefulness of CTL assay and DTH in monitoring cannot be determined solely by the verification at this time, the possibility of observing many clinical reactions could be shown for CEA652 (9) in cases where positive conversion was observed.
- Published
- 2007
42. [A case of gastric cancer with multiple liver metastases effectively treated by hepatic arterial infusion of MMC, TS-1/CDDP therapy, and thermotherapy].
- Author
-
Ogata T, Nishida J, Seo K, Hamaya M, Kouno T, Sato S, Yoshida K, Tsuchida A, and Aoki T
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma secondary, Cisplatin administration & dosage, Combined Modality Therapy, Drug Administration Schedule, Drug Combinations, Hepatic Artery, Humans, Infusions, Intra-Arterial, Liver Neoplasms drug therapy, Liver Neoplasms therapy, Male, Middle Aged, Mitomycin administration & dosage, Oxonic Acid administration & dosage, Pyridines administration & dosage, Remission Induction, Stomach Neoplasms drug therapy, Tegafur administration & dosage, Adenocarcinoma therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hyperthermia, Induced, Liver Neoplasms secondary, Stomach Neoplasms pathology, Stomach Neoplasms therapy
- Abstract
A 62-year-old man was revealed to have type 2 gastric cancer with synchronous liver metastasis. We considered liver metastasis to be a prognostic factor, and performed two courses of combination thermochemotherapy consisting of hepatic arterial infusion of MMC and TS-1 and thermotherapy. Partial response was observed in the liver metastases,but the primary lesion showed no changes; therefore, we performed four courses of combination thermochemotherapy consisting of TS-1/CDDP therapy and thermotherapy. By the end of three courses of this therapy,the primary lesion had cicatrized,and endoscopic biopsy revealed no cancer cells. These results suggest that gastric cancer,in which liver metastasis is considered to be a prognostic factor,can be effectively treated by combination therapy with hepatic arterial infusion therapy, followed by thermochemotherapy for the primary lesion.
- Published
- 2005
43. [Two case reports on intra-tumor injection therapy of dendritic cells].
- Author
-
Kanazawa M, Yoshihara K, Abel H, Suzuki S, Endoh Y, Onogi H, Ohki S, Takita K, Sekikawa K, Takenoshita S, Takagi T, Irisawa A, Satoh Y, Ogata T, and Ohto H
- Subjects
- Aged, Cell Movement physiology, Humans, Injections, Intralesional, Lymphatic Metastasis, Male, Middle Aged, Phagocytosis, T-Lymphocytes, Cytotoxic immunology, Dendritic Cells immunology, Esophageal Neoplasms therapy, Immunotherapy methods, Sarcoma, Clear Cell therapy
- Abstract
DC (dendritic cells) vaccine therapy against cancer has attracted attention in recent years. However, the existence of the immunosuppressive state in cancer individuals leads to anergy and failure in cytotoxic T cell (CTL) induction and DC migration to the target organ. It has been reported that injected intra-tumor DC is expected to work phagocytosis of the tumor as a localized effect, the consequent CTL induction in the tumor and the regional lymphnodes, resulting in a systemic effect. Two cases reported in this article were performed with intra-tumor DC injection therapy by means of EUS (endoscopic ultrasonography) which indicated interesting immunoreaction.
- Published
- 2005
44. [Experimental study for a combination chemo-immunotherapy using dendritic cells].
- Author
-
Kashimura S, Terashima M, Soeta N, Otani S, Hoshino M, Kanzaki N, Matsuyama S, Hoshino Y, Kogure M, Gotoh M, Ogata T, and Ohto H
- Subjects
- Adult, Apoptosis physiology, Docetaxel, Humans, Immunotherapy methods, In Vitro Techniques, Leukocytes, Mononuclear physiology, Lymphocyte Activation drug effects, Membrane Glycoproteins analysis, Receptors, Cell Surface analysis, T-Lymphocytes, Cytotoxic physiology, Toll-Like Receptor 4, Toll-Like Receptors, Tumor Cells, Cultured, Antineoplastic Agents, Phytogenic administration & dosage, Dendritic Cells transplantation, Paclitaxel administration & dosage, Stomach Neoplasms therapy, Taxoids administration & dosage
- Abstract
This study was designed to seek for the optimal anticancer agents for a combination of chemotherapy and specific immunotherapy using dendritic cells (DC) in gastric cancer. We investigated the immuno-suppressive activity of anticancer agents on human peripheral blood mononuclear cells (PBMC), apoptosis inducing activity on gastric cancer cells and expression of Toll-like receptor (TLR)-4 mRNA on immatureDCs (iDCs) by paclitaxel (TXL) and docetaxel (TXT). We further compared the cytotoxicity of cytotixic T lymphocytes (CTLs) induced by DCs pulsed with tumor cell lysate and apoptotic cells induced by TXT. Although most of the anticancer agents demonstrated the suppression activity on proliferation of PBMC in a dose dependent manner, TXT, doxifluridine and irinotecan did not show the suppressive activity on PBMC even in the highest drug concentration. About 60% of gastric cancer cells demonstrated apoptosis after a 24-48 hour treatment with both TXL and TXT. Expression of TLR-4 mRNA in iDCs was up-regulated by TXT, not by TXL, and peaked at 2 hours after the treatment. CTLs induced by DCs pulsed with tumor cell lysate and apoptotic cells showed a similar killing activity to target cells. These results suggest that TXT appears to be an optimal anticancer agent for a combination therapy with chemotherapy and tumor specific immunotherapy using dendritic cells in gastric cancer.
- Published
- 2004
45. [Case report on intra-tumor injection therapy of dendritic cells in advanced gastric cancer].
- Author
-
Kanazawa M, Yoshihara K, Abe H, Iwadate M, Watanabe K, Suzuki S, Endoh Y, Ohki S, Takita K, Sekikawa K, Takenoshita S, Takagi T, Irisawa A, Sato Y, Ogata T, and Ohto H
- Subjects
- Endosonography, Female, Humans, Immunotherapy methods, Injections, Intralesional, Middle Aged, Dendritic Cells transplantation, Stomach Neoplasms therapy
- Abstract
Dendritic cells (DC) are powerful antigen-presenting cells, and have attracted attention in recent years from the viewpoint of DC vaccine therapy against cancer. However, the existence of an immunosuppressive state in cancer individuals leads to anergy and failure in cytotoxic T cell (CTL) induction and DC migration to the target organ. It has been reported that injected intra-tumor DCs are expected to work phagocytosis of the tumor as a localized effect. Consequently CTL induction in the tumor and the regional lymphnodes results in a systemic effect. In this study, intra-tumor DC injection therapy was performed by means of endoscopic ultrasonography (EUS) in 2 gastric cancer cases. As a result, tumor markers and ascites of one case were on the decrease. The results indicate this method can be useful in advanced cancer patients.
- Published
- 2004
46. [Chemoradiation therapy for stage IV pancreatic cancer].
- Author
-
Horiuchi H, Ishikawa H, Hayashi K, Uchida S, Kodama T, Nishimura K, Ogata T, Yasunaga M, Ohdo M, Hara M, Okuda K, Kinoshita H, Aoyagi S, and Shirouzu K
- Subjects
- Adult, Aged, Combined Modality Therapy, Drug Administration Schedule, Female, Humans, Intraoperative Care, Male, Middle Aged, Neoplasm Staging, Pancreatectomy, Pancreatic Neoplasms mortality, Pancreatic Neoplasms surgery, Radiotherapy Dosage, Survival Rate, Gemcitabine, Antimetabolites, Antineoplastic administration & dosage, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms radiotherapy
- Abstract
Background: Pancreatic cancer is a malignant tumor with a poor prognosis. It frequently presents with locally advanced and distant metastasis at the time of diagnosis. Favorable results were obtained by performing intraoperative radiation therapy (IORT) and chemotherapy (administration of GEM) for the treatment of inoperable pancreatic cancer. A study was conducted on its efficacy as an adjuvant therapy for inoperable and advanced pancreatic cancer., Subjects and Methods: Between May 1998 and December 2002, 40 patients with stage IV pancreatic cancer were treated at our institution. The study comprised background factors, adjuvant therapy and survival rate., Results: According to the treatment modality, the study population was classified into four groups: group A, consisting of 3 patients with localized unresectable tumors who had been treated with IORT: group B, 5 patients who underwent curative resection of primary tumor combined with IORT: group C, 6 patients who were administered GEM combined with IORT: group D, 26 patients not falling into groups A, B or C. The mean survival for group A, B, C and D was 10.3 months, 6.7 months, 16.8 months and 9.4 months, respectively. The 1-year survival rates were 0%, 0%, 80.0% and 19.3%, respectively. The mean survival and the 1-year survival rate were significantly better in group C than in the other groups. In group C, the tumor decreased in size, invasion of large vessels and pancreatic posterior evolution was suppressed, and 4 patients survived for 17 months or more., Conclusions: Prolongation of the survival period was shown by concomitant IORT and administration of GEM for inoperable advanced pancreatic cancer. Thus, attempting to combine chemotherapy with IORT and giving additional consideration to the administration method was shown to provide adjuvant therapy that can be expected to be effective against stage IV inoperable pancreatic cancer.
- Published
- 2003
47. [Effect of DC therapy combined with chemotherapy in advanced cancer cases].
- Author
-
Kanazawa M, Mori Y, Yoshihara K, Iwadate M, Suzuki S, Endoh Y, Takita K, Sekikawa K, Takenoshita S, Ogata T, and Ohto H
- Subjects
- CD4 Antigens blood, Colonic Neoplasms immunology, Combined Modality Therapy, Cytokines blood, Humans, Interleukin-10 blood, Interleukin-12 blood, Killer Cells, Lymphokine-Activated transplantation, Receptors, Interleukin-2 blood, Stomach Neoplasms immunology, T-Lymphocytes, Cytotoxic immunology, Th1 Cells immunology, Adjuvants, Immunologic administration & dosage, Colonic Neoplasms therapy, Dendritic Cells transplantation, Proteoglycans administration & dosage, Stomach Neoplasms therapy
- Abstract
Dendritic cells (DC) are powerful antigen-presenting cells, and have attracted attention in recent years from the viewpoint of DC vaccine therapy against cancer. However, the existence of an immunosuppressive state in cancer individuals leads to anergy and immunotolerance, which has been reported to be caused by T cell and DC immunosuppressive subsets or cytokines such as Th2, Tc2, CD4+CD25+, DC2 and IL-10 against Th1, Tc1, DC1 and IL-12. Therefore, DC therapy could be incompatible with severe chemotherapy. Conversely, there are some reports that indicate tumor specific cytotoxicity in DC therapy could be augmentedly un exposure to tumor antigen caused by apoptosis in combination radiation or chemotherapy. In this study we examined the usefulness of DC therapy combined with chemotherapy and BRM (PSK) administration by analyzing the immunocyte subsets and cytokines as well as the combination effect. The results indicate this method can be useful in advanced cancer patients.
- Published
- 2003
48. [Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC].
- Author
-
Kamiyama T, Matsushita M, Kurauchi N, Nakagawa T, Kamachi H, Kondo M, Ito T, Ogata T, Nishikawa M, and Todo S
- Subjects
- Adult, Aged, Carcinoma, Hepatocellular mortality, Drug Combinations, Female, Fluorouracil administration & dosage, Hepatic Artery, Humans, Infusions, Intra-Arterial, Liver Neoplasms mortality, Male, Middle Aged, Survival Rate, Tegafur administration & dosage, Uracil administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Hepatocellular drug therapy, Infusion Pumps, Implantable, Liver Neoplasms drug therapy
- Abstract
Unlabelled: Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC)., Method: Modified PMC consists of medication with UFT and intraarterial infusion of 5-FU. The dose of UFT is 300 or 400 mg/day. The infusion to hepatic artery of 5-FU is performed with 500 mg/body in an outpatient clinic once a week from reservoir port for 5 hours., Results: The number of recurrent cases after hepatectomy was 5, and that of initial cases with unresectable HCC was 3. Three cases had tumor thrombus in the main portal branch. One patient had tumor thrombus in the inferior vena cava, which reached to the right atrium. The mean number of infusions in all cases was 21. One case showed PR, and 3 cases NC. Three of 6 mortality cases died from liver failure without tumor progression. One year survival rates of the patients with tumor thrombus in the portal trunk or IVC were 75.0%. The mean survival period of these cases was 12.5 +/- 4.2 months., Conclusion: Modified PMC had no severe side effect and was effective for advanced unresectable HCC.
- Published
- 2002
49. [Comparative study on quality of life between weekly and monthly chemotherapy with cisplatin, vindesine and mitomycin C in patients with non-small cell lung cancer].
- Author
-
Ishihara Y, Ichiwata T, Kuramitsu K, Yoneda S, Yamamoto M, Takizawa T, Ogata T, Uchiyama T, and Yoshida K
- Subjects
- Adult, Aged, Carcinoma, Non-Small-Cell Lung physiopathology, Carcinoma, Non-Small-Cell Lung psychology, Cisplatin administration & dosage, Drug Administration Schedule, Female, Humans, Lung Neoplasms physiopathology, Lung Neoplasms psychology, Male, Middle Aged, Mitomycin administration & dosage, Vindesine administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Quality of Life
- Abstract
A comparative study between weekly and monthly chemotherapy with CDDP, VDS and MMC was performed on the basis of QOL in patients (stage III A/III B/IV) with non-small lung cancer from September 1993 to August 1996. Arm A received CDDP (80 mg/m2) monthly on day 1, VDS (3 mg/m2) on days 1 and 8, MMC (8 mg/m2) on day 1. Arm B received CDDP (40 mg/m2), VDS (3 mg/m2) and MMC (4 mg/m2) on day 1, and followed by CDDP (20 mg/m2), VDS (1.5 mg/m2) and MMC (2 mg/m2) weekly. A diary-type QOL self-rating questionnaire was devised for this study, consisting of 5 scales including 13-item questionnaires and a face scale as the global scale. Chronological QOL data from 20 days during chemotherapy (total dose of CDDP was 80 mg/m2 in both A and B arm) were analyzed using summary measures. In the 78 eligible subjects of the study, 34 were QOL subjects of the 27 eligible subjects, 13 were in arm A and 14 in arm B. 1. The questionnaire was confirmed to be satisfactory with regard to reliability and validity as a questionnaire for the evaluation of this study by factor and correlation analysis. 2. Although each scale changed to the worth level after chemotherapy, there was no significant difference between arm A and B. 3. Summary statistics were assessed using indices of the area under the curve (AUC) and the maximum fluctuations of QOL scores (Dif max) arm B showed a tendency to smaller changes than arm A in AUC and Dif max. There was a significant difference in the physical well-being scale of Dif max. 4. Three items, including the physical well-being in arm B, revealed a better score than those of arm A. Abdominal condition showed a significant difference between the two arms. 5. No obvious difference in anti-cancer effectiveness was found between arm A and B. Arm B showed a longer median survival, less nausea and vomiting, leukopenia and thrombocytopenia compared with arm A. The above results suggested that weekly chemotherapy is as effective, less toxic and shows less influence against patients QOL than the conventional monthly chemotherapy in this study.
- Published
- 1998
50. [A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
- Author
-
Yokota T, Fujii T, Roppongi T, Kanno K, and Ogata T
- Subjects
- Bone Neoplasms secondary, Breast Neoplasms pathology, Carcinoma, Ductal, Breast secondary, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Doxorubicin analogs & derivatives, Drug Administration Schedule, Female, Fluorouracil administration & dosage, Humans, Liver Neoplasms secondary, Lung Neoplasms secondary, Lymphatic Metastasis, Middle Aged, Antineoplastic Agents, Hormonal administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Carcinoma, Ductal, Breast drug therapy, Medroxyprogesterone Acetate administration & dosage
- Abstract
A 59-year-old female complaining of breast tumor with suppurative discharge was diagnosed as having advanced breast cancer (T4cN3M1-StIV), with giant liver metastasis. Seven courses of combined chemoendocrine therapy (CTF + MPA) were used. Following the chemoendocrine therapy, primary tumor, lung, pleural, supraclavicular and parasternal metastasis disappeared, and the liver metastasis was obviously diminished. These effects continued for 1 year 7 months. Although CTF + MPA chemoendocrine therapy is widely used with advanced or recurrent breast cancer, a clearly effective case has almost never been reported. The reason for the remarkable effect in this case was the consistent immunity to breast cancer.
- Published
- 1998
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.